Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (108)	8/1/2000 8:26:56 PM
From: Peter Goss	Respond to of 724

Rick - you're welcome. I not a scientist but think biotech is very interesting investment ground. It is amazing to look at Waters market cap and valuations and measure against NBSC. WAT gets 10x sales - if NBSC can bring margins and ROE up a bit - get out from under that backorder cloud - it might get something along that line. Plus, NBSC has the hidden power of DGI that somebody may discover. Then, with a small float off we go. Best, Peter

To: scaram(o)uche who wrote (108)	8/2/2000 11:15:24 AM
From: scaram(o)uche	Read Replies (3) \| Respond to of 724

Joe Kernan, CNBC, says that Advanced Medicine IPO has been pulled. "Unfavourable market conditions". Huh????? Maybe they are doing a bit of panning. <g> Wednesday August 2, 11:01 am Eastern Time Gates-backed Advanced Medicine withdraws IPO WASHINGTON, Aug 2 (Reuters) - Advanced Medicine Inc., a drug discovery company backed by Microsoft Corp. (NasdaqNM:MSFT - news) co-founder Bill Gates, withdrew on Wednesday a $172.5 million initial public offering because of unfavourable market conditions. The San Francisco-based company, which originally filed for the IPO with the Securities and Exchange Commission in March, had applied for a Nasdaq listing under the symbol ``ADVM'' (Nasdaq:ADVM - news). The offering was going to be jointly handled by Goldman Sachs and Merrill Lynch, with assistance from Bear Stearns. Advanced Medicine's objective is to discover, develop and commercialize new drugs as well as improve existing ones using a special technology. Some of its biggest investors includes Gates, one of the world's richest men, who holds a 7.5 percent stake equal to 2.9 million shares, according to Advanced Medicine's IPO filing.